{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT03373877","nct_id":"NCT03373877","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03373877. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Cohort 1","label":"Dose 1: PU-H71 225 mg/m2 + ruxolitinib","type":"EXPERIMENTAL"},{"description":"Cohort 2","label":"Dose 2: PU-H71 300 mg/m2 + ruxolitinib","type":"EXPERIMENTAL"},{"description":"Cohort 3","label":"Dose 3: PU-H71 400 mg/m2 + ruxolitinib","type":"EXPERIMENTAL"},{"description":"Cohort 4","label":"Dose 4: PU-H71 600 mg/m2 + ruxolitinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2020-03-10","type":"ACTUAL"},"conditions":["Myelofibrosis","Primary Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis"],"enrollment":{"count":4,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"PU-H71","otherNames":[],"type":"DRUG"},{"name":"Ruxolitinib","otherNames":["Jakafi"],"type":"DRUG"}],"last_update":"2022-11-15","lead_sponsor":"Samus Therapeutics, Inc.","official_title":"A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)","overall_status":"TERMINATED","phases":["PHASE1"],"primary_completion_date":{"date":"2019-10-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Incidence of adverse events","timeFrame":"12 months"},{"measure":"Maximum Tolerated Dose of PU-H71 (MTD)","timeFrame":"7 months"},{"measure":"Recommended Phase 2 Dose of PU-H71 (RP2D)","timeFrame":"12 months"},{"measure":"Pharmacokinetic profile of PU-H71: Area under the plasma concentration versus time curve (AUC)","timeFrame":"12 months"},{"measure":"Pharmacokinetic profile of PU-H71: Trough plasma concentration (Cmin)","timeFrame":"12 months"},{"measure":"Pharmacokinetic profile of PU-H71: Peak plasma concentration (Cmax)","timeFrame":"12 months"},{"measure":"Pharmacokinetic profile of PU-H71: Time to maximum plasma concentration (Tmax)","timeFrame":"12 months"},{"measure":"Pharmacokinetic profile of PU-H71: Plasma half-life (T1/2)","timeFrame":"12 months"}],"references":[],"start_date":{"date":"2018-05-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis","url":"https://clinicaltrials.gov/study/NCT03373877"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03373877"}